4SC: Landmark RESMAIN study data presented at the 5th World Congress of Cutaneous Lymphomas
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 202…
. - BAY 2927088 ist ein oraler, niedermolekularer Tyrosinkinase-Inhibitor, in der Entwicklung als potenzielle neue zielg…
KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partn…
Large quantities of the protein IGF2BP2 not only make bowel cancer grow faster, but they also make it resistant to commo…
Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for ad…
Eckert & Ziegler Radiopharma GmbH (EZR), the radiopharmaceutical production arm of Eckert & Ziegler, has signed a joint…
Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed an agreement with Telix Pharmaceuticals (Telix), an Australian-h…
Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have executed a long-term supply agreement f…
Jeder Tumor ist einzigartig wie ein Fingerabdruck und kann zunehmend patientenindividuell behandelt werden, daher sollte…